Benzinga | Apr 19, 2021 08:13AM EDT

Catalyst Biosciences Highlights Publication Of CB 2679d Preclinical FIX Gene Therapy Data In Blood Journal of the American Society of Hematology

Catalyst Biosciences, Inc. (NASDAQ:CBIO) today announced the publication of preclinical data from its study of CB 2679d-GT in Hemophilia B mice in Blood, the peer-reviewed, official journal of the American Society of Hematology. The paper, entitled: "Gene Therapy for Hemophilia B Using CB 2679d-GT: A Novel Factor IX Variant with Higher Potency than Factor IX Padua," demonstrated superiority of the Company's CB 2679d-GT gene therapy candidate over that of the R338L-Padua variant, which is currently used in clinical trials.